Literature DB >> 28189573

Relationship between Mean Fluorescence Intensity and C1q/C3d-fixing capacities of anti-HLA antibodies.

Guillaume Claisse1, Lena Absi2, Fabrice Cognasse3, Eric Alamartine4, Christophe Mariat5, Nicolas Maillard6.   

Abstract

BACKGROUND: Complement-binding assays are proposed to better stratify the risk of antibody-mediated rejection associated-graft failure. Despite promising clinical results, some have suggested that the MFI of anti-HLA antibodies may influence these tests.
METHODS: We investigated the impact of Abs MFI reduction, induced by plasmapheresis, on C1q- and C3d-binding assays. Sera provided from 7 sensitized kidney transplant patients were analyzed.
RESULTS: Four hundreds and thirty-three SABs were analyzed. Before plasmapheresis, when compared to C1q- SABs, C1q+ SABs had a higher median MFI [17397 (IQR: 14851-18794) vs. 2745 (IQR: 1125-6476), p<0.01]. SABs that remained C1q+ after plasmapheresis had a higher median MFI. Regarding the C3d assay, results were strictly comparable. MFI value was a powerful predictor of both C1q and C3d positivity [AUC 0.97 (CI95% 0.95-0.99) and 0.96, (CI95% 0.93-0.98), respectively].
CONCLUSION: Our data suggest that both C1q- and C3d-binding assays are intimately linked to the MFI of anti-HLA Abs.
Copyright © 2017 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C1q; C3d; LUMINEX; MFI; PROZONE

Mesh:

Substances:

Year:  2017        PMID: 28189573     DOI: 10.1016/j.humimm.2017.02.003

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

Review 1.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

2.  Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.

Authors:  Hyeyoung Lee; Eunhee Han; Ae-Ran Choi; Tae Hyun Ban; Byung Ha Chung; Chul Woo Yang; Yeong Jin Choi; Eun-Jee Oh
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

3.  Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome.

Authors:  Maria Meneghini; Edoardo Melilli; Jaume Martorell; Ignacio Revuelta; Elisabet Rigol-Monzó; Anna Manonelles; Nuria Montero; David Cucchiari; Fritz Diekmann; Josep M Cruzado; Salvador Gil-Vernet; Josep M Grinyó; Oriol Bestard
Journal:  Kidney Int Rep       Date:  2018-03-30

4.  C3d-Positive Preformed DSAs Tend to Persist and Result in a Higher Risk of AMR after Kidney Transplants.

Authors:  Sooin Choi; Kyo Won Lee; Jae Berm Park; Kyunga Kim; Hye-Ryeon Jang; Wooseong Huh; Eun Suk Kang
Journal:  J Clin Med       Date:  2020-01-30       Impact factor: 4.241

Review 5.  Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report.

Authors:  Anat R Tambur; Patricia Campbell; Anita S Chong; Sandy Feng; Mandy L Ford; Howard Gebel; Ronald G Gill; Garnett Kelsoe; Vasilis Kosmoliaptsis; Roslyn B Mannon; Michael Mengel; Elaine F Reed; Nicole M Valenzuela; Chris Wiebe; I Esme Dijke; Harold C Sullivan; Peter Nickerson
Journal:  Am J Transplant       Date:  2020-05-27       Impact factor: 8.086

Review 6.  Application, technical issues, and interpretation of C1q for graft outcome.

Authors:  Dolly B Tyan
Journal:  Curr Opin Organ Transplant       Date:  2017-10       Impact factor: 2.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.